MAP4K4 and familial dilated cardiomyopathy: The present study demonstrated that silencing or inhibiting MAP4K4 (DMX-5804) in DCM significantly improved microvascular density, angiogenesis, and endothelial-dependent microvascular perfusion by activating the VEGF and eNOS signaling pathways.